Login to Your Account

EMA diverges from FDA on etelcalcetide in SHPT; reverses its position on ixazomib in myeloma

By Cormac Sheridan
Staff Writer

Friday, September 16, 2016

DUBLIN – The FDA's surprise rejection of Amgen Inc.'s application for approval of Parsabiv (etelcalcetide) in secondary hyperparathyroidism is now looking even more curious, as the same drug is set to gain approval in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription